S0600
Clone Type
MonoclonalHost
MouseIsotype
IgG1,kClone Number
8.F.254Grade
Affinity PurifiedApplications
EShipping Temp
Blue IceStorage Temp
-20°CMouse Anti-Secobarbital
Barbiturates are a class of around 12 compounds derivatized from barbituric acid. They are central nervous system (CNS) depressants and can be used as sedatives, hypnotics, anaesthetics and anti-epileptic drugs. Barbiturates can be divided into three main groups according to their duration of action. The ultra-short-acting barbiturates are used clinically as anaesthetics while the long-acting barbiturates have anti-convulsant properties. The short-acting compounds are typically used as hypnotics (1, 2). The short-acting barbiturates are extensively metabolised by the liver to more pharmacologically inactive hydroxylated compounds. Only a small proportion of parent compound (<0.2%) appears in the urine collected after 24 hours. However, with large doses, there is usually sufficient of the parent compound present to give an adequate response and some of the hydroxylated metabolites will also crossreact in immunoassays (1).
Applications
Suitable for use in ELISA. Other applications not tested.
Recommended Dilution
Optimal dilutions to be determined by the researcher.
Affinity Constant
~3.0x10e7 L/mole
Storage and Stability
May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Immunogen
Secobarbital-BSA
Form
Supplied as a liquid in PBS, pH 7.2, 0.05% sodium azide.
Purity
Purified by Protein A affinity chromatography.
Specificity
Recognizes barbituates
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
References
General References::|1. Galloway, J.H., et al., (1999), “Detection of drug misuse and addictive challenge”, J. Clin. Pathol.,|52(10): 713-718|2. Manchikanti, L., (2006), Prescription drug abuse: what is being done to address this new drug epidemic?|Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources”, Pain Physician, 9(4): 287-321USBio References
No references available